Revenue segments as reported by the company.

MedSurg and Neurotechnology

Orthopaedics and Spine

Orthopaedics

MedSurg

Neurotechnology and Spine

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research, development and engineering

Selling, general and administrative

Recall charges

Amortization of intangible assets

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Stryker

MAKO was a publicly traded medical device company based in Florida. On September 25, 2013, the Board of Directors of Mako Surgical accepted a deal to be acquired by Stryker for $1.65B. The deal closed in December 2013. The company manufactures and markets surgical robotic arm assistance platforms, most notably the RIO as well as orthopedic implants used by orthopedic surgeons for use in partial knee and total hip arthroplasty. They are known for their intellectual property of devices and have over 300 U.S. and foreign patents and patent applications.

MAKO Surgical Corp

Stryker Corp. is a medical technology company, which engages in the provision of products and services that help improve patient and healthcare outcomes. It operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The MedSurg and Neurotechnology segment includes surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull based surgical procedures, orthobiologic, and biosurgery. The Orthopaedics and Spine segment focuses on implants used in hip and knee joint replacements and trauma and extremity surgeries, and cervical, thoracolumbar, and interbody systems used in spinal injury, deformity, and degenerative therapies. The company was founded by Homer H. Stryker in 1941 and is headquartered in Portage, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Stryker (SYK) exceeds Q4 expectations, poised for growth in 2023

Stryker (SYK) delivered exceptional financial results in Q4 2022, surpassing expectations and demonstrating resilience amid challenges. The company is well-positioned for growth with a strong pipeline of products and a focus on margin expansion. Despite ongoing market complexities, Stryker remains optimistic about its future performance.

Stryker reports robust Q1 results and optimistic outlook for 2023

Stryker's strong Q1 performance driven by organic sales growth and increased EPS, with positive outlook for the full year.
Company recognized for workplace excellence, leading in robotics, and expecting growth in medical division.
Challenges include supply chain uncertainties, margin impacts, and market disruptions, but opportunities lie in stakeholder engagement and business expansion.
Overall, Stryker remains focused on innovation, debt reduction, and strategic acquisitions for future growth.

Stryker reports stellar Q2 results, eyes international growth opportunities

Stryker's Q2 performance reflects robust sales growth, margin improvement, and strategic acquisitions driving financial strength.
While facing challenges in the U.S. market and competitive landscapes, Stryker's focus on innovation and international growth presents promising opportunities.
The company's financial resilience, debt reduction strategy, and upcoming product launches position Stryker for sustained success and market expansion.
Overall, Stryker's strong performance, coupled with a focus on innovation and strategic growth initiatives, sets a positive trajectory for future success.

Stryker reports robust Q3 earnings, eyes international growth and M&A

Stryker's Q3 performance reflects strong sales growth and earnings increase, driven by key segments and product lines. Challenges include market competition and potential shifts in procedure trends, while opportunities exist in international expansion and strategic acquisitions.

Stryker exceeds $20B in sales, eyes continued growth and innovation

Stryker's Q4 performance showcased strong sales growth, margin expansion, and successful acquisitions, positioning the company for continued success.
While facing challenges in pricing and potential regulatory impacts, Stryker's focus on innovation and strategic growth initiatives presents promising opportunities.
The company's robust pipeline of innovative products and successful integration efforts highlight its resilience and potential for sustained growth.
With a solid financial foundation and strategic vision, Stryker is well-positioned to capitalize on market opportunities and drive future profitability.

Stryker reports strong Q1 growth, eyes international expansion opportunities

Stryker's Q1 2024 earnings call reflects strong performance, with double-digit organic sales growth and increased guidance for the full year.
The company's focus on innovation, successful acquisitions, and market recognition position it well for future growth and leadership in key segments.
While facing challenges like regulatory delays and market dependencies, Stryker remains optimistic about meeting targets and driving growth through new products and acquisitions.
Opportunities in international expansion, AI solutions, and continued market growth present avenues for sustained success and market leadership for Stryker.

Stryker reports robust Q2 earnings, raises 2024 outlook on acquisitions and margin expansion

Stryker's strong Q2 performance, strategic acquisitions, and focus on margin expansion position the company for continued growth. Despite challenges like foreign exchange rates and market softness in certain segments, Stryker's product strength, innovation pipeline, and international growth opportunities offer a positive outlook. With a commitment to driving margins and expanding its product portfolio, Stryker remains poised for sustained success in the medical technology industry.

Stryker reports robust Q3 performance with strong growth and strategic acquisitions

Stryker's Q3 showcased strong organic sales and EPS growth, driven by MedSurg and Neurotechnology segments.
Strategic acquisitions, record Mako installations, and operational efficiency improvements underpin performance.
Challenges in the ischemic stroke segment and competitor actions pose risks, while pricing trends and margin efficiencies are under scrutiny.
Opportunities lie in M&A expansion, growth in high-demand areas, and sustained market momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Stryker Corporation (NYSE:SYK ) Q1 2023 Earnings Conference Call May 1, 2023 4:30 PM ET Company Participants Kevin Lobo - Chair and Chief Executive Officer Jason Beach - Vice President, Investor Relations Glenn Boehnlein - Vice President, Chief Financial Officer Conference Call Participants Lawrence Biegelsen - Wells Fargo Securities Robert Marcus - JPMorgan Joanne Wuensch - Citibank Vijay Kumar - Evercore ISI Matthew O'Brien - Piper Sandler Ryan Zimmerman - BTIG Eric Anderson - TD Cowen Matt Miksic - Barclays Travis Steed - Bank of America Steven Lichtman - Oppenheimer & Company Rick Wise - Stifel Matthew Mishan - KeyBanc Capital Markets Imron Zafar - Deutsche Bank Richard Newitter - Truist Securities Danielle Antalffy - UBS Jeffrey Johnson - Baird Kyle Rose - Canaccord Operator Good day and welcome to the First Quarter 2023 Stryker Earnings Call. My name is Todd and I'll be your operator for today's call.

Stryker Corporation (SYK) Q1 2023 Earnings Call Transcript

Stryker (SYK) came out with quarterly earnings of $2.14 per share, beating the Zacks Consensus Estimate of $2 per share. This compares to earnings of $1.97 per share a year ago.

Stryker (SYK) Tops Q1 Earnings and Revenue Estimates

Kalamazoo, Michigan, May 01, 2023 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2023:

Stryker reports first quarter 2023 operating results

Edwards Lifesciences

Medtronic

Medtronic has raised its dividend for 45 consecutive years. Edwards Lifesciences had a strong first quarter and upgraded 2023 guidance.

3 Medical Device Stocks Outpacing the Healthcare Industry This Year

Stryker operates in the medical sector and is engaged in the innovation and sale of medical equipment internationally. SYK has new offerings that partially contributed to its revenues.

Stryker: Consistently Innovative With Steady Profits And Dividends

Abbott Labs

Accenture Plc

AGCO

Arthur J. Gallagher & Co.

Clorox

ConocoPhillips

Carlisle Companies

Coterra Energy

D.R. Horton

Dick's Sporting Goods

EOG Resources

Expeditors International of Washington

Marsh & McLennan

Owens Corning

SAP SE

Steel Dynamics

Tractor Supply

Visa

We explain why selling cash-covered puts and covered calls are relatively safe choices for earning a high income. We will discuss how to formulate an options income strategy that's sustainable and repeatable.

Earn Double-Digit Income With Options (May 2023)

Stryker Corporation's innovative surgical solutions position the company to capitalize on the growing demand for joint replacement technology.

3 Reasons To Consider Buying Stryker Corporation

Boston Scientific

DexCom

The healthcare sector has been looking fit in the past month, with medical products makers Stryker Corp. (NYSE: SYK) and Boston Scientific Corp. (NYSE: BSX) rallying to all-time highs, while sector peer DexCom Inc. (NASDAQ: DXCM) is forming a constructive base.

Healthcare Innovation Drives Medical Device Makers To New Highs

Stryker, Edwards Lifesciences and Boston Scientific shares outperform the broader healthcare sector as procedure volumes rebound and costs stabilize.

Medical-Device Makers Gain Amid Return to Normalcy

Does Stryker (SYK) have what it takes to be a top stock pick for momentum investors? Let's find out.

Stryker (SYK) is a Great Momentum Stock: Should You Buy?

Bristol-Myers

Bristol Myers Squibb and Stryker are both developing life-changing products for patients. The two companies each pay growing dividends to shareholders.

2 Top Stocks to Buy in April and Hold Forever

Kalamazoo, Michigan, March 30, 2023 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for first quarter of fiscal year 2023 on Monday, May 1, 2023.  A press release will be issued at approximately 4:05pm ET and available at Stryker - Press Releases that day. The press release will include summary financial information for the company's first quarter of fiscal year 2023, which ends on Friday, March 31, 2023.

Stryker to announce financial results for its first quarter of fiscal year 2023

DENVER--(BUSINESS WIRE)--The first clinical use of Stryker's Tornier Pyrocarbon Humeral Head was completed at Denver Surgery Center in Colorado.

Stryker Now Offers the Only FDA-Cleared Pyrocarbon Bearing Material Option for Shoulder Hemiarthroplasty

Agilent Technologies

Apple

Agnico Eagle Mines

Applied Materials

Churchill Downs

KLA-Tencor

Microsoft

Old Dominion Freight Line

PulteGroup

Skyworks Solutions

TFI International

Earn Double-Digit Income With Options (April 2023)

Henry Schein

Syneos Health

MedTech player like Medtronic (MDT) are integrating artificial intelligence (AI) capabilities to aid therapeutic and diagnostic applications.

MedTech Bigwigs in Spotlight as AI Revolutionizes Healthcare

Allegro MicroSystems

BJ`s Wholesale Club Holdings Inc

CrowdStrike

Dell Technologies

Oracle

TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, including BJ's & CrowdStrike

Top Wall Street analysts pick these five stocks for the long term

Fortis

Bank OZK

Income investors value reliability and consistency, as well as high dividend yields. Some stocks provide a combination of these factors, such as the Dividend Champions — stocks that have raised their payouts for at least 25 years in a row.

3 Dividend Champions for Long-Term Income

Align Technology

Lantheus Holdings

Penumbra

Large-cap medical device maker Stryker Corp. (NYSE: SYK) is consolidating along its 50-day moving average, a bullish sign as the stock takes a breather after a run-up that began last year.

Are These Medical Device Makers Getting Ready To Rally?

EssilorLuxottica SA

ESLOY vs. SYK: Which Stock Is the Better Value Option?

Fiserv

Powell believes returning to bigger rate hikes could be necessary if data suggests the U.S. economy is heating up again. Is this the correct path to take?

Navigating Volatility: 3 Stocks Worthy of Consideration

KALAMAZOO, Michigan, USA, March 2, 2023 /PRNewswire/ -- Stryker (NYSE:SYK) announced the launch of its CD NXT System, the latest innovation in the company's power tools. This patented technology provides real-time depth measurement as the surgeon drills, allowing for fast, accurate, consistent digital depth measurement across various procedures.

CD NXT power tool system empowers surgeons through real-time depth measurement

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Stryker (SYK) is a Top Growth Stock for the Long-Term

KALAMAZOO, Mich.--(BUSINESS WIRE)--Stryker (NYSE:SYK), one of the world's leading medical technology companies, today announced that its Q Guidance System with Cranial Guidance Software received 510(k) clearance from the U.S. Food and Drug Administration. The Q Guidance System is an image-based planning and intraoperative guidance system designed to support cranial surgeries. Recently launched in September 2022, the Q Guidance System for spinal applications is currently available on the market.

Stryker's Q Guidance System for cranial applications receives FDA clearance

News for Stryker Stock (SYK)